Chae SH, et al. - In surgically managed early-stage uterine leiomyosarcoma (uLMS) cases, how the risk of recurrence is influenced by adjuvant chemotherapy (AC) or radiotherapy (AR) was determined via this meta-analysis. PubMed, EMBASE, and MEDLINE, and Cochrane databases were searched for relevant publications up to March 2019. The eligible studies were those that compared early-stage uLMS cases treated with AC or AR to those not treated with AC or AR. This analysis included randomized trials (n=3) and observational studies (n=9): 9 studies for AC vs observation, n = 496; 9 studies for AR vs observation, n = 425. Findings revealed that no attenuation in the recurrence rate was achieved with AC, including gemcitabine/docetaxel regimen, or AR in patients with early-stage uLMS.